First-generation systemic therapy, comprising cytokine-based procedures including interferon-alpha (IFN-α) and interleukin-2(IL-2), is recommended for advanced RCC patients since there is documented evidence for its effectiveness against advanced RCC. The gene discussed is IL2; the disease is renal cell adenocarcinoma.